Positive Phase 3 Data on Stivarga in Gastrointestinal Stromal Tumors

Share this content:

Bayer HealthCare announced the results from a pivotal Phase 3 study for Stivarga (regorafenib); the GRID (GIST - Regorafenib In Progressive Disease) trial provides evidence for the efficacy of regorafenib in patients with gastrointestinal stromal tumor (GIST). Regorafenib is an oral multi-kinase inhibitor that inhibits various kinases that are involved in mechanisms associated with oncogenesis, angiogenesis, and the tumor microenvironment.

GRID was a randomized, double-blind, placebo-controlled, multi-center, cross-over study. It randomized 199 patients whose disease had progressed despite prior treatment with imatinib (Gleevec; Novartis) and sunitinib (Sutent; Pfizer). Patients were randomized in a 2:1 ratio to receive either regorafenib (160mg once daily, 3 weeks on/1 week off) plus best supportive care (BSC) or placebo plus BSC.  Patients initially randomized to placebo were allowed to cross over to open-label regorafenib once the disease progressed, of which 85% of the patients from the placebo arm did cross over.

The trial showed that regorafenib plus BSC significantly improved progression-free survival (PFS) vs. placebo plus BSC (HR=0.27, P<0.000001). The median PFS was 4.8 months in the regorafenib arm vs. 0.9 months in the placebo arm. In addition, there was a positive trend in the regorafenib group in improving overall survival (OS) (HR=0.772, P=0.199); however, the OS did not reach statistical significance.

Furthermore, a significantly greater disease control rate (DCR) was observed with regorafenib plus BSC compared to placebo plus BSC (52.6% vs. 9.1%; P<0.000001), DCR was defined as rate of complete response [CR] plus partial response [PR] plus durable stable disease [SD] maintained for at least 12 weeks. In addition, regorafenib demonstrated therapeutic benefit independent of prior treatment options based on analysis in pre specified subgroups that showed regorafenib had a statistically significant PFS benefit over placebo for patients receiving regorafenib as a third- or fourth-line treatment.

Stivarga is approved for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

For more information call (800) 288-8371 or visit www.bayerpharma.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs